Loading…
The test demonstrated high accuracy in detecting esophageal cancer.
ProPhase Labs, Inc. announced ProPhase Labs announced the successful completion of a validation study for the BE-Smart Test, demonstrating its high accuracy in detecting esophageal cancer.
The announcement cited >95%, 79%, 750%, 6-7 million, 50%, and 73 million.
ProPhase Labs, Inc. has a free float of 42,845,800 shares and 46,179,000 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.